Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatmen
An assessment of 6-month progression-free survival in patients with mCRC with third-line and postline metastatic colorectal cancer in combination with cardonilizumab and fuquinitinib and SBRT compared with fuquinitinib monotherapy
| Condition(s) | Metastatic Colorectal Cancer |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | An assessment of 6-month progression-free survival in patients with mCRC with third-line and postline metastatic colorectal cancer in combination with cardonilizumab and fuquinitinib and SBRT compared with fuquinitinib monotherapy |
| Who can participate | Inclusion Criteria:• Provision of written Informed Consent Form (IC) prior to any study specific procedures * Age = 18 years, $75 years * Histologically or cytologically confirmed advanced Stage IV primary colorectal cancer * MSI status: MSS * At least two or more standard systemic therapies prior treatment (based on Fu, oxaliplatin, irinotecan, bevacizumab and cetuximab) of cytotoxic chemotherapy, treatment failure or intolerable toxicities * ECOG 0-1 * Patients must have measurable lesions * Expected overall survival ≥ 12 weeks * AST, ALT and alkaline phosphatase s 2.5 times the upper limit of normal (ULN), Serum bilirubin s 1.5 x ULN, creatinine\<ULN * Prothrombin time (PT), international standard ratio (INR) ≤ 1.5 × ULN * Patients are allowed to have received radiotherapy, but the time |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Lead sponsor | Liu Huang |
| Locations | Wuhan, Hubei, China |
| Start date | 2024-08-20 |
| NCT ID | NCT06551207 |
| Official listing | https://clinicaltrials.gov/study/NCT06551207 |